King B, Ko J, Forman S, et al. - Researchers conducted this Phase 2 study of adults with alopecia areata (BRAVE-AA1) to assess baricitinib’s efficacy as well as safety in patients with ≥ 50% scalp hair loss. Patients were randomly assigned 1:1:1:1 to receive placebo, baricitinib 1-mg, 2-mg, or 4-mg once daily. Experts carried out two consecutive interim analyses after all patients completed Weeks 12 and 36 or had stopped treatment before these time points. In baricitinib 2-mg and 4-mg groups, a significantly greater proportion of patients achieved Severity of Alopecia Tool score ≤20 at Week 36, compared with placebo. Good tolerability of baricitinib was evident with no new safety findings. Overall, baricitinib’s efficacy and safety in patients with ≥ 50% scalp hair loss is supported by the findings of this study.